Grifols

GRFS - GrifolsFinancials

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2016
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2017
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2018
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2019
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2020
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2021
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2022
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2023
7,287
1,358
-
0.6%
0.14
5,935
0.8%
11,483
8.5
240
-343
190
-103
0
0
-
0%
12/2024
7,505
1,696
-
2%
0.48
6,122
3%
9,306
5.5
939
-387
-1,414
552
0
-2
1.3%
0.082%
12/2025
8,828
1,986
-
5%
1.4
6,184
8%
10,304
5.2
1,228
-496
-621
732
0
-300
64%
9.4%